Loading
A phase 1/2 trial of Mezigdomide, Bortezomib, Dexamethasone in multiple myeloma, run by Celgene, active and no longer recruiting.
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) is a phase 1/2 interventional study registered as NCT03989414 by Celgene, with 424 participants planned, started 2019-09-30 and due to reach its primary completion in 2026-11-30. Interventions recorded: CC-92480, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Cereblon E3 ligase modulators (CELMoDs), Carfilzomib, Daratumumab, Bortezomib.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Carfilzomib, Dexamethasone.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Bortezomib, Dexamethasone.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Cereblon E3 ligase modulators (CELMoDs), Daratumumab, Bortezomib, Dexamethasone.
Shares Mezigdomide, Carfilzomib, Daratumumab, Dexamethasone.
Shares Elotuzumab, Carfilzomib, Bortezomib, Dexamethasone.